Grifols SA (GRFS)
NASDAQ:GRFS
Want to see GRFS full AI Analyst Report?
Earnings Data
Report Date
Jul 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.28Last Year’s EPS
0.2Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a largely constructive operational and financial picture: solid revenue growth, strong Biopharma and IG momentum, margin resilience, disciplined OpEx reductions, meaningful balance-sheet and liquidity improvements, and a strategically significant ramp in Egyptian plasma sourcing that supports long-term margin expansion. Near-term headwinds—most notably albumin weakness in China, a decline in Alpha‑1 & specialty proteins (driven in part by prior-year inventory effects and access frictions), reported Diagnostics revenue impact from the Quidel Ortho JV dissolution, seasonally negative free cash flow in Q1 and FX translation pressure—were acknowledged as largely temporary or manageable and offset by active mitigation plans (pricing/market access initiatives, center optimization, platform launches, and compensation from the JV dissolution). Overall, positives in execution, capital structure and strategic positioning materially outweigh the temporary operational and market challenges highlighted by management.Company Guidance
Quarterly Revenue Growth
Reported revenues of EUR 1.7 billion in Q1 2026, representing +3.3% growth at constant currency versus prior year.
Adjusted EBITDA and Margin Resilience
Adjusted EBITDA of EUR 381 million reported (EUR 404 million at constant currency). Adjusted EBITDA margin broadly stable at 22.4% with +0.8% adjusted EBITDA growth at constant currency year-over-year.
Strong Biopharma Performance Led by Immunoglobulins
Biopharma revenue grew 6.8% at constant currency. Immunoglobulins (IG) delivered +15.3% year-over-year growth at constant currency, driven by Gamunex momentum and strong double-digit demand for Xembify; Xembify expected to deliver strong double-digit growth for the full year.
Profitability and Bottom Line Improvement
Group profit increased 22% year-over-year to EUR 73 million in Q1 2026, reflecting operational resilience despite currency translation headwinds.
OpEx Discipline
Operating expenses reduced by 7.7% at constant currency versus Q1 2025, contributing to margin preservation and demonstrating cost control.
Balance Sheet Strengthening and Liquidity
Net leverage improved to 4.3x (down 0.2 turns year-over-year). Successful refinancing eliminated near-term 2027 maturities, upsized and extended revolver to >$2 billion with 6.5-year maturity, and reduced refinancing risk until Q4 2028.
Debt/Credit Improvements
Partial redemption of EUR 500 million 7.5% bonds executed and strong investor demand enabled structural improvements; two of three rating agencies upgraded Grifols back into the BB space.
Strategic Plasma Sourcing Expansion (Egypt)
EMA approval for Egyptian-sourced plasma; target to collect ~1 million liters in Egypt in 2026 and scale to ~3 million liters by 2029. Management expects ex-U.S. plasma volumes to increase ~2.5x by 2029, enabling cost per liter (CPL) optimization and improved margin dynamics over time.
Diagnostics Long-Term Catalysts and Autonomous Strategy
On a like-for-like basis (excluding Quidel Ortho joint-venture dissolution), Diagnostics grew in the low single digits. Company to receive USD 65 million compensation over 3 years from JV dissolution and plans to launch the Barcelona Next Generation blood-typing platform in Q2 2026 and ISARD immunoassay platform to expand addressable markets.
Operational Actions to Improve Productivity
Closure/optimization of 29 underperforming U.S. donor centers to consolidate into higher-performing locations, expected to improve plasma network quality and contribute to CPL and margin improvements without major incremental industrial capital.
GRFS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GRFS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $8.41 | $8.06 | -4.16% |
Feb 26, 2026 | $9.25 | $8.96 | -3.14% |
Nov 04, 2025 | $9.43 | $9.22 | -2.23% |
Jul 29, 2025 | $9.96 | $10.36 | +4.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Grifols SA (GRFS) report earnings?
Grifols SA (GRFS) is schdueled to report earning on Jul 23, 2026, Before Open (Confirmed).
What is Grifols SA (GRFS) earnings time?
Grifols SA (GRFS) earnings time is at Jul 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GRFS EPS forecast?
GRFS EPS forecast for the fiscal quarter 2026 (Q2) is 0.28.